| Combination antiretroviral therapy and the risk of myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group New England Journal of Medicine 349 (21), 1993-2003, 2003 | 2104 | 2003 |
| Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study Data Collection on Adverse Events of Anti-HIV Drugs Study Group Archives of internal medicine 166 (15), 1632-1641, 2006 | 1488 | 2006 |
| Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study A Rauch, Z Kutalik, P Descombes, T Cai, J Di Iulio, T Mueller, M Bochud, ... Gastroenterology 138 (4), 1338-1345. e7, 2010 | 1461 | 2010 |
| Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study G Greub, B Ledergerber, M Battegay, P Grob, L Perrin, H Furrer, ... The Lancet 356 (9244), 1800-1805, 2000 | 1243 | 2000 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration D: A: D Study Group The Lancet 371 (9622), 1417-1426, 2008 | 1160 | 2008 |
| Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study B Ledergerber, M Egger, M Opravil, A Telenti, B Hirschel, M Battegay, ... The Lancet 353 (9156), 863-868, 1999 | 1114 | 1999 |
| Maraviroc for previously treated patients with R5 HIV-1 infection RM Gulick, J Lalezari, J Goodrich, N Clumeck, E DeJesus, A Horban, ... New England Journal of Medicine 359 (14), 1429-1441, 2008 | 907 | 2008 |
| Cognitive dysfunction in HIV patients despite long-standing suppression of viremia S Simioni, M Cavassini, JM Annoni, AR Abraham, I Bourquin, V Schiffer, ... Aids 24 (9), 1243-1250, 2010 | 893 | 2010 |
| Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study M Egger, B Hirschel, P Francioli, P Sudre, M Wirz, M Flepp, M Rickenbach, ... Bmj 315 (7117), 1194-1199, 1997 | 770 | 1997 |
| AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study B Ledergerber, M Egger, V Erard, R Weber, B Hirschel, H Furrer, ... Jama 282 (23), 2220-2226, 1999 | 626 | 1999 |
| CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study GR Kaufmann, L Perrin, G Pantaleo, M Opravil, H Furrer, A Telenti, ... Archives of internal medicine 163 (18), 2187-2195, 2003 | 559 | 2003 |
| Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study J Fellay, B Ledergerber, E Bernasconi, H Furrer, M Battegay, B Hirschel, ... The Lancet 358 (9290), 1322-1327, 2001 | 484 | 2001 |
| Les personnes séropositives ne souffrant d’aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle P Vernazza, B Hirschel, E Bernasconi, M Flepp Bulletin des médecins suisses| Schweizerische Ärztezeitung| Bollettino dei …, 2008 | 477 | 2008 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 437 | 2010 |
| Characteristics, Determinants, and clinical relevance of CD4 T cell recovery to< 500 cells/µL in HIV type 1—infected individuals receiving potent antiretroviral therapy GR Kaufmann, H Furrer, B Ledergerber, L Perrin, M Opravil, P Vernazza, ... Clinical infectious diseases 41 (3), 361-372, 2005 | 435 | 2005 |
| Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection G Fätkenheuer, M Nelson, A Lazzarin, I Konourina, AIM Hoepelman, ... New England Journal of Medicine 359 (14), 1442-1455, 2008 | 426 | 2008 |
| Turnover of CD4+ and CD8+ T Lymphocytes in HIV-1 Infection as Measured by Ki-67 Antigen N Sachsenberg, AS Perelson, S Yerly, GA Schockmel, D Leduc, ... The Journal of experimental medicine 187 (8), 1295-1303, 1998 | 405 | 1998 |
| HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. M Opravil, M Pechère, R Speich, HI Joller-Jemelka, R Jenni, EW Russi, ... American journal of respiratory and critical care medicine 155 (3), 990-995, 1997 | 382 | 1997 |
| Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1–infected adults treated with combination antiretroviral therapy H Furrer, M Egger, M Opravil, E Bernasconi, B Hirschel, M Battegay, ... New England Journal of Medicine 340 (17), 1301-1306, 1999 | 356 | 1999 |
| A controlled trial of zidovudine in primary human immunodeficiency virus infection S Kinloch-de Loës, BJ Hirschel, B Hoen, DA Cooper, B Tindall, A Carr, ... New England Journal of Medicine 333 (7), 408-413, 1995 | 356 | 1995 |
